209 related articles for article (PubMed ID: 37895146)
1. H-Dot Mediated Nanotherapeutics Mitigate Systemic Toxicity of Platinum-Based Anticancer Drugs.
Yamashita A; Park SH; Zeng L; Stiles WR; Ahn S; Bao K; Kim J; Kang H; Choi HS
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895146
[TBL] [Abstract][Full Text] [Related]
2. Convection-enhancement delivery of platinum-based drugs and Lipoplatin(TM) to optimize the concomitant effect with radiotherapy in F98 glioma rat model.
Shi M; Fortin D; Sanche L; Paquette B
Invest New Drugs; 2015 Jun; 33(3):555-63. PubMed ID: 25784204
[TBL] [Abstract][Full Text] [Related]
3. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2014 Jul; (7):CD009219. PubMed ID: 24984156
[TBL] [Abstract][Full Text] [Related]
4. Comparative adverse effect profiles of platinum drugs.
McKeage MJ
Drug Saf; 1995 Oct; 13(4):228-44. PubMed ID: 8573296
[TBL] [Abstract][Full Text] [Related]
5. Platinum-based drugs for cancer therapy and anti-tumor strategies.
Zhang C; Xu C; Gao X; Yao Q
Theranostics; 2022; 12(5):2115-2132. PubMed ID: 35265202
[TBL] [Abstract][Full Text] [Related]
6. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2012 May; (5):CD009219. PubMed ID: 22592737
[TBL] [Abstract][Full Text] [Related]
7. Toxicities of the platinum antineoplastic agents.
Markman M
Expert Opin Drug Saf; 2003 Nov; 2(6):597-607. PubMed ID: 14585068
[TBL] [Abstract][Full Text] [Related]
8. Medical interventions for the prevention of platinum-induced hearing loss in children with cancer.
van As JW; van den Berg H; van Dalen EC
Cochrane Database Syst Rev; 2019 May; 5(5):CD009219. PubMed ID: 31063591
[TBL] [Abstract][Full Text] [Related]
9. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
10. Platinum compounds in children with cancer: toxicity and clinical management.
Ruggiero A; Trombatore G; Triarico S; Arena R; Ferrara P; Scalzone M; Pierri F; Riccardi R
Anticancer Drugs; 2013 Nov; 24(10):1007-19. PubMed ID: 23962902
[TBL] [Abstract][Full Text] [Related]
11. Toxicity of platinum compounds.
Hartmann JT; Lipp HP
Expert Opin Pharmacother; 2003 Jun; 4(6):889-901. PubMed ID: 12783586
[TBL] [Abstract][Full Text] [Related]
12. Neurotoxicity Associated with Platinum-Based Anti-Cancer Agents: What are the Implications of Copper Transporters?
Stojanovska V; McQuade R; Rybalka E; Nurgali K
Curr Med Chem; 2017; 24(15):1520-1536. PubMed ID: 28079002
[TBL] [Abstract][Full Text] [Related]
13. The Power of Kinetic Inertness in Improving Platinum Anticancer Therapy by Circumventing Resistance and Ameliorating Nephrotoxicity.
Panda TR; M M; Vaidya SP; Chhatar S; Sinha S; Mehrotra M; Chakraborty S; Gadre S; Duari P; Ray P; Patra M
Angew Chem Int Ed Engl; 2023 Sep; 62(38):e202303958. PubMed ID: 37314332
[TBL] [Abstract][Full Text] [Related]
14. Carboplatin versus cisplatin in solid tumors: an analysis of the literature.
Lokich J; Anderson N
Ann Oncol; 1998 Jan; 9(1):13-21. PubMed ID: 9541678
[TBL] [Abstract][Full Text] [Related]
15. Membrane transporters as determinants of the pharmacology of platinum anticancer drugs.
Liu JJ; Lu J; McKeage MJ
Curr Cancer Drug Targets; 2012 Oct; 12(8):962-86. PubMed ID: 22794121
[TBL] [Abstract][Full Text] [Related]
16. Advancements in the Use of Platinum Complexes as Anticancer Agents.
Sharma R; Singh VJ; Chawla PA
Anticancer Agents Med Chem; 2022; 22(5):821-835. PubMed ID: 34353272
[TBL] [Abstract][Full Text] [Related]
17. [About side effects of platinum drugs].
Waszkiewicz K
Postepy Hig Med Dosw; 2001; 55(3):387-406. PubMed ID: 11505639
[TBL] [Abstract][Full Text] [Related]
18. Ototoxicity and Platinum Uptake Following Cyclic Administration of Platinum-Based Chemotherapeutic Agents.
Gersten BK; Fitzgerald TS; Fernandez KA; Cunningham LL
J Assoc Res Otolaryngol; 2020 Aug; 21(4):303-321. PubMed ID: 32583132
[TBL] [Abstract][Full Text] [Related]
19. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
Raynaud FI; Boxall FE; Goddard PM; Valenti M; Jones M; Murrer BA; Abrams M; Kelland LR
Clin Cancer Res; 1997 Nov; 3(11):2063-74. PubMed ID: 9815598
[TBL] [Abstract][Full Text] [Related]
20. Risk of Vascular Toxicity with Platinum Based Chemotherapy in Elderly Patients with Bladder Cancer.
Gupta A; Long JB; Chen J; Gross CP; Feldman DR; Steingart RM
J Urol; 2016 Jan; 195(1):33-40. PubMed ID: 26341576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
